Topoisomerase IIα: Prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum

International Journal of Gynecological Pathology

Volumn 19, Issue 3, 2000, Pages 248-257

  Costa, Michael J ^a   Hansen, Christian L ^b   Holden, Joseph A ^c   Guinee Jr , Donald ^d  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Carcinoma; Immunohistochemistry; Ovary; Topoisomerase

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; PLATINUM DERIVATIVE; PROTEIN P21; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CELL CYCLE; DISEASE MARKER; EPITHELIUM TUMOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OVARY TUMOR; PERITONEUM TUMOR; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

EID: 0033922173     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-200007000-00009     Document Type: Article

References (62)

1. Hand R, Fremgen A, Chmiel JS, Recant W, Berk R, Sylvester J, Sener S. Staging procedures, clinical management, and survival outcome for ovarian carcinoma. J Am Med Assoc 1993;269: 1119-22.
2. Piver MS, Baker TR, Piedmonte M, Sanedecki AM. Epidemiology and etiology of ovarian cancer. Semin Oncol 1991;18:177-85.
3. Hendrickson MR, Longacre TA. Classification of surface epithelial neoplasms of the ovary. In: Hendrickson MR, ed. Surface Epithelial Neoplasms of the Ovary. Pathology: State of the Art Reviews. Philadelphia; Hanley & Belfus, 1993:189-254.
4. Cramer SF, Roth LM, Ulbright TM, et al. Evaluation of the reproducibility of the Word Health Organization classification of common ovarian cancers. Arch Pathol Lab Med 1987;111:819-29.
5. Shimizu Y, Kamio S, Amada S, Hasoui K, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma. Gynecol Oncol 1998;70: 2-12.
6. Holden JA. Human deoxyribonucleic acid TopoIIaisomerases: molecular targets of anticancer drugs. Ann Clin Lab Science 1997;27: 402-11.
7. Burden DA, Osheriff N. Mechanisms of action of eukaryotic TopoIIaisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:139-54.
8. Dingemans AMC, Pinedo HM, Giaccone G. Clinical resistance to TopoIIaisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400:275-8.
9. Hande KR. Clinical applications of anticancer drugs targeted to TopoIIaisomerase II. Biochem Biophys Acta 1998;1400: 173-84.
10. Guinee DG, Holden JA, Benfield JR, et al. Comparison of DNA TopoIIaisomerasse lia expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer 1996;78:729-35.
11. Lynch BJ, Guinee DG, Holden JA. Human DNA TopoIIaisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 1997;28:1180-8.
12. Iino K, Sasano H, Yabuki N, Oki Y, Kikuchi A, Yoshimi T, Nagura H. DNA TopoIIaisomerase IIα and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol 1997;10:901-7
13. van der Zee AGJ, Hollema H, de Jong S, et al. P-glycoprotein expression and DNA TopoIIasiomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991, 51:5915-20.
14. van der Zee AGJ, de Jong S, Keith WN, Hollema H, Boonstra H, de Vries EGE. Quantitative and qualitative aspects of TopoIIaisomerase I and IIα and β in untreated and platinum/ cyclophosphamide treated malignant ovarian tumors. Cancer Res 1994, 54:749-55.
15. Tanoguchi K, Sasano H, Yabuki N, Kikuchi A, Ito K, Sato S, Yajima A. Immunohistochemical and two parameter flow cytometric studies of DNA TopoIIaisomerase IIα human epithelial ovarian carcinoma and aerm cell tumor. Mod Pathol 1998;11: 186-93.
16. Martinchick JC, Rahn MP, Jolles CJ, Holden JA. Human DNA TopoIIaisomerase II-α: Immunohistochemical staining for enzyme protein in tumors of ovarian origin. Int J Oncol 1997;10:1229-34.
17. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70:523-526.
18. Marx J. How p53 suppresses cell growth. Science 1993; 262: 1644-1645.
19. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential Mediator of p53 Tumor Suppression. Cell 1993;75:817-25.
20. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54 :1169-74.
21. Zhang W, Grasso L, McClain CD, et al. p53-independent Induction of WAF/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 1995;55:668-74.
22. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF/CIP1 by a p53-independent pathway. Cancer Res 1994; 54 :3391-5.
23. Gildas J, Nguyen H, Li T, Hill D, Cowan KH. Effects of Cell cycle, wild-type p53 and DNA damage on p21 CIP/Waf1 expression in human breast epithelial cells. Oncogene 1995;11:253-61.
24. Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM, Dotto GP. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci 1995;92:5451-5.
25. Chiarugi V, Magnelli L, Cinelli M, Basi G. Apoptosis and the cell cycle. Cell Mol Bio Res 1994;40:603-12.
26. Gerdes J, Li L, Schlueter C, Duchrow M, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138: 867-73.
27. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168: 357-63.
28. Barbareschi M, Girlando S, Mauri FM, et al. Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol 1994;102:171-5.
29. Gallion HH, Pieretti M, DePriest PD, van Nagell JR Jr. The molecular basis of ovarian cancer. Cancer 1995;76(10 Suppl.): 1992-7.
30. Kupryjanczyk J, Thor A, Beauchamp R, et al. p53 gene mutation and protein accumulation in human ovarian cancer. Proc Natl Acad Sci 1993;90:4961-5.
31. Kupryjanczyk J, Bell DA, Yandell DW, Scully RE, Thor AD. p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 1994;102:671-6.
32. Kupryjanczyk J, Bell DA, Dimeo D, Beuchamp R, Thor AD, Yandell DW. p53 gene analysis of ovarian borderline tumors and stage 1 carcinomas. Hum Pathol 1995;26:387-92.
33. Klemi PJ, Takahashi S, Joensuu H, Kiilholma P, Narimatsu E, Mori M. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994;13:228-33.
34. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993;24:1175-9.
35. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-8.
36. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC Jr, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993;81:643-50.
37. Kiyokawa T. Alteration of p53 in ovarian cancer: its occurrence and maintenance in tumor progression. Int J Gynecol Pathol 1994; 13:311-8.
38. Kounelis S, Papadaki H, Kanbour-Shakir A, Bakker, Swalsky PA, Finkelstein SD. p53 point mutational damage predicts tumor recurrence in ovarian adenocarcinoma [Abstract]. Mod Pathol 1995; 8:92A.
39. Lee JH, Kang YS, Park SY, et al. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet 1995;85:41-50.
40. Marchenko ND, Moll UM. Nuclear overexpression of p53 protein does not correlate with gene mutation in primary peritoneal carcinoma. Hum Pathol 1997;28:1002-6.
41. Righetti SC, Della Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;5:689-93.
42. Buttitta F, Marchetti A, Gadducci A, et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997;75:230-5.
43. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV, Fontana JA. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: Role of p53-dependent and independent signal transduction pathways. Oncogene 1994;9:3407-15.
44. Bonfanti M, Taverna S, Salmona M, D'Incalci M, Broggini M. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res 1997; 57:1442-6.
45. Steinman R, Hofftnan B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994;9:3389-96.
46. Palazzo JP, Mercer WE, Kovatich AJ, McHugh M. Immunohistochemical localization of p21 WAF1/CIP1 in normal, hyperplastic and neoplastic uterine tissue. Hum Pathol 1997;27:60-6.
47. Auer G, Einhorn N, Nilsson B, Silfversward C, Sjovall K. Biological malignancy srading in early-stage ovarian carcinoma. Acta Oncol 1996; 35 Suppl 8:93-8.
48. Wan M, Cofer KF, Dubeau L. WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer. Brit J of Cancer 1996;73:1398-400.
49. Jordan PA, Kerns BM, Pence JC, Kohler MF, Bast RC, Kinney RB, Berchuck A. Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 1993; 99:736-40.
50. Kerns BM, Jordan PA, Faerman LL, Berchuck A, Bast RC, Layfield LJ. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 1994;101:192-77
51. Jussila T, Stenbäck F. Cell proliferation markers and growth factors in ovarian cancer. Ann Med 1995;27:87-94.
52. Henricksen R, Strang P, Wilander E, Bäckström T, Tribukait B, Öberg K. p53 expression in epithelial ovarian neoplasm: Relationship to clinical and pathological parameters, Ki67 expression and flow cytometry. Gynecol Oncol 1994;53:301-6.
53. WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer 1995; 63:611-5.
54. Gibb RK, Taylor DD, Wan T, O'Connor DM, Doering DL, Gercel-Taylor C. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol 1997; 65:13-22.
55. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996; 56:2178-84.
56. O'Hanlan KA. Principles of surgical management of ovarian carcinomas. In: Hendrickson MR, ed. Surface Epithelial Neoplasms of the Ovary: Pathology: State of the Art Reviews. Philadelphia: Hanley & Belfus, 1993:477-89.
57. Costa MJ, Hansen C, Dickerman A, Scudder SA. The climcopathologic significance of the transitional cell carcinoma pattern in non-localized ovarian epithelial tumors (stage 2-4). Am J Clin Pathol 1998; 109:173-80.
58. Costa MJ, Kenny M, Judd R. Uterine glandular carcinoma. Correlation of histologic classification, immunohistochemistry and grading with origin and outcome. Int J Surg Pathol 1993;1:13-24
59. Hendrickson MR, Longacre TA, Kempson RL. Clinicopathology of malignant surface epithelial neoplasms of the ovary. In: Hendrickson MR, ed. Surface Epithelial Neoplasms of the Ovary. Pathology: State of the Art Reviews. Philadelphia: Hanley & Belfus, 1993:367-410.
60. Costa MJ, Hansen CL, Walls J, Scudder SA. Immunohistochemical markers of ell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21 WAF1/CIP1 predicts survival and good response to platinin based chemotherapy. Human Pathol 1999;30:640-7.
61. Duncan R C, Knapp RC, Miller MC III. Introductory Biostatistics for the Health Sciences. New York: John Wiley & Sons, Inc., 1983.
62. Vollmer RT. Multivariate statistical analysis for anatomic pathology. Part II: failure time analysis. Am J Clin Pathol 1996;106: 522-34.